Methoxyamine hydrochloride is a Small Molecule owned by TRACON Pharmaceuticals, and is involved in 8 clinical trials, of which 4 were completed, 3 are ongoing, and 1 is planned.

TRC102 (methoxyamine hydrochloride) acts by covalently binding to apurinic/apyrimidinic (AP) DNA damage sites and inhibits base excision repair (BER), which results in an increase in DNA strand breaks and apoptosis. It blocks the ability of a cell to repair DNA damage and kill the cancer cells.

The revenue for Methoxyamine hydrochloride is expected to reach a total of $384m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Methoxyamine hydrochloride NPV Report.

Methoxyamine hydrochloride was originated by Case Western Reserve University and is currently owned by TRACON Pharmaceuticals.

Methoxyamine hydrochloride Overview

TRC-102 (methoxyamine hydrochloride) is under development for the treatment of advanced or metastatic solid tumors, lung cancer, glioblastoma multiforme (GBM), lymphoma, ovarian cancer, colorectal cancer, mesothelioma. It is administered through oral and intravenous route. It is an inhibitor of base-excision repair intended to reverse resistance to alkylator and antimetabolite chemotherapy. It was under development for the treatment of relapsed or refractory hematologic malignancies, multiple myeloma,chronic lymphocytic leukemia (CLL), chronic myelocytic leukemia, Hodgkin Lymphoma, diffuse large B-Cell lymphoma, nodal T-Cell Lymphomas, mantle cell lymphoma, anaplastic large cell lymphoma and follicular lymphoma

TRACON Pharmaceuticals Overview

TRACON Pharmaceuticals (TRACON) is a biopharmaceutical company. It develops and commercializes targeted therapies for cancer, age-related macular degeneration and fibrotic diseases. The company offers pipeline products such as TRC105, TRC102, TJ004309, TRC253, TRC694, and TRC205. Its lead product TRC105, is an anti-endoglin antibody that is being developed for the treatment of multiple solid tumor types in combination with VEGF inhibitors. TRC102 is a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma. In addition, it also offers products for the treatment of fibrosis, prostate cancer, and hematologic malignancies such as myeloma. The company works in collaboration with universities and medical institutions. TRACON is headquartered in San Diego, California, the US.

The company reported revenues of (US Dollars) US$0.4 million for the fiscal year ended December 2021 (FY2021). The operating loss of the company was US$28.4 million in FY2021, compared to an operating loss of US$16.2 million in FY2020. The net loss of the company was US$28.7 million in FY2021, compared to a net loss of US$16.8 million in FY2020.

Quick View – Methoxyamine hydrochloride

Report Segments
  • Innovator
Drug Name
  • Methoxyamine hydrochloride
Administration Pathway
  • Intravenous
  • Oral
Therapeutic Areas
  • Oncology
Key Companies
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.